Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 5
2005 3
2006 7
2007 4
2009 2
2010 3
2012 4
2013 2
2014 2
2015 2
2016 4
2017 1
2018 1
2019 1
2020 3
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Rausch J, et al. Among authors: burrows f. Haematologica. 2023 Oct 1;108(10):2837-2843. doi: 10.3324/haematol.2022.282160. Haematologica. 2023. PMID: 37102614 Free PMC article. No abstract available.
Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer.
Jagadeeshan S, Prasad M, Badarni M, Ben-Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, Ho AL, Rosenberg AJ, Kessler L, Burrows F, Kong D, Grandis JR, Gutkind JS, Elkabets M. Jagadeeshan S, et al. Among authors: burrows f. Cancer Res. 2023 Apr 4;83(7):1031-1047. doi: 10.1158/0008-5472.CAN-22-2586. Cancer Res. 2023. PMID: 36753744 Free PMC article.
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villaflor V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S. Smith AE, et al. Among authors: burrows f. Cancer Res. 2023 Oct 2;83(19):3252-3263. doi: 10.1158/0008-5472.CAN-23-0282. Cancer Res. 2023. PMID: 37339176 Free PMC article.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: burrows f. Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23. Leukemia. 2022. PMID: 36151141 Free PMC article. No abstract available.
Hsp90 activation and cell cycle regulation.
Burrows F, Zhang H, Kamal A. Burrows F, et al. Cell Cycle. 2004 Dec;3(12):1530-6. doi: 10.4161/cc.3.12.1277. Epub 2004 Dec 30. Cell Cycle. 2004. PMID: 15539946 Review.
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S, Suryamohan K, Shin N, Mathukkada S, Boyko A, Melikhova D, Tsareva A, Yunusova L, Pravdivtseva E, Stupichev D, Shaposhnikov K, Peterson A, Bednyagin L, Shugaev-Mendosa E, Kessler L, Burrows F, Ho AL, Agrawal N, Pearson AT, Izumchenko E, Cole G, Elkabets M, Rosenberg AJ. Jagadeeshan S, et al. Among authors: burrows f. Oral Oncol. 2024 Feb;149:106688. doi: 10.1016/j.oraloncology.2024.106688. Epub 2024 Jan 13. Oral Oncol. 2024. PMID: 38219706
Therapeutic and diagnostic implications of Hsp90 activation.
Kamal A, Boehm MF, Burrows FJ. Kamal A, et al. Among authors: burrows fj. Trends Mol Med. 2004 Jun;10(6):283-90. doi: 10.1016/j.molmed.2004.04.006. Trends Mol Med. 2004. PMID: 15177193 Free PMC article. Review.
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber T, Choi S, Sun D, Ren P, Li LS, Liu Y, Burrows F, Maillard I, Cierpicki T, Grembecka J. Klossowski S, et al. Among authors: burrows f. J Clin Invest. 2020 Feb 3;130(2):981-997. doi: 10.1172/JCI129126. J Clin Invest. 2020. PMID: 31855575 Free PMC article.
51 results